Initial results of a phase i trial of continuous infusion SR 2508 (etanidazole): A radiation therapy oncology group study
- 1 April 1989
- journal article
- clinical trial
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 16 (4) , 1085-1087
- https://doi.org/10.1016/0360-3016(89)90922-x
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Chemical modifiers of cancer treatment.Journal of Clinical Oncology, 1988
- Phase I trial of the hypoxic cell radiosensitizer SR-2508: The results of the five to six week drug scheduleInternational Journal of Radiation Oncology*Biology*Physics, 1986
- A phase I study of the combination of two hypoxic cell radiosensitizers, Ro 03-8799 and SR-2508: Toxicity and pharmacokineticsInternational Journal of Radiation Oncology*Biology*Physics, 1986
- Hypoxic cell radiosensitizers: Expectations and progress in drug developmentInternational Journal of Radiation Oncology*Biology*Physics, 1985
- Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508International Journal of Radiation Oncology*Biology*Physics, 1984
- Clinical trials of radiosensitizers: What should we expect?International Journal of Radiation Oncology*Biology*Physics, 1984
- Clinical perspectives for the use of new hypoxic cell sensitizersInternational Journal of Radiation Oncology*Biology*Physics, 1982
- Radiosensitization of the RIF-1 murine flank tumor by desmethylmisonidazole (Ro 05 9963) during interstitial brachytherapyInternational Journal of Radiation Oncology*Biology*Physics, 1982
- The enhanced sensitivity of mammalian cells to killing by X rays after prolonged exposure to several nitroimidazolesInternational Journal of Radiation Oncology*Biology*Physics, 1982
- SR-2508: A 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical useInternational Journal of Radiation Oncology*Biology*Physics, 1981